Journal Watch · Briefings in Bioinformatics · 2026

Machine learning-guided multimodal profiling defines perturbed immune states at the time of cancer diagnosis.

This supports future development of immune-based diagnostics and disease monitoring approaches.

Berlin P, Mirzaei A, Steinbeck F et al.Briefings in Bioinformatics3 min readPharma relevance 75/100

DOI: 10.1093/bib/bbag320PMID: 42308424Study type: cohort / observational clinical study

TL;DR

This supports future development of immune-based diagnostics and disease monitoring approaches.

Key findings

  • Together, these findings establish a framework for immune-based, multi-omics profiling of peripheral blood and provide a resource for discovering circulating cancer-associated immune signatures.
  • This supports future development of immune-based diagnostics and disease monitoring approaches.

What they did

Compared with healthy donors, patients exhibited widespread immune dysregulation, including expansion of FOXP3+ regulatory T cells, depletion of CD16+CD11b+ monocytes and CD56^dim^ Natural killer (NK) cells, and elevated plasma IL-6 and IL-4 levels. scRNA-seq identified cancer-associated immune signatures, notably consistent upregulation of THBS1 and CH25H, indicative of systemic imprinting by tumour-derived cues. We further developed machine learning-guided models integrating single-cell multi-omics data (sc-FC and scRNA-seq) to characterize cancer-associated immune patterning and cancer type-related signal structure, while providing biologically interpretable feature attribution across modalities. The models achieved robust classification performance within the cohort and revealed modality-spanning features linked to immune state alterations.

Full abstract (original)

Background: Altered immune states at the time of cancer diagnosis remain insufficiently characterized. Although circulating immune biomarkers offer a promising, non-invasive way of analysing systemic tumour-host interactions, their potential remains poorly defined. Here, we present an integrated multi-omics analysis of peripheral blood mononuclear cells from treatment-naïve cancer patients, minimizing confounding by therapy-induced immune changes, combining immune phenotyping (flow cytometry, FC), multiplex cytokine profiling, and single-cell RNA sequencing (scRNA-seq).

What they did: Compared with healthy donors, patients exhibited widespread immune dysregulation, including expansion of FOXP3+ regulatory T cells, depletion of CD16+CD11b+ monocytes and CD56^dim^ Natural killer (NK) cells, and elevated plasma IL-6 and IL-4 levels. scRNA-seq identified cancer-associated immune signatures, notably consistent upregulation of THBS1 and CH25H, indicative of systemic imprinting by tumour-derived cues. We further developed machine learning-guided models integrating single-cell multi-omics data (sc-FC and scRNA-seq) to characterize cancer-associated immune patterning and cancer type-related signal structure, while providing biologically interpretable feature attribution across modalities. The models achieved robust classification performance within the cohort and revealed modality-spanning features linked to immune state alterations.

Results & conclusions: Together, these findings establish a framework for immune-based, multi-omics profiling of peripheral blood and provide a resource for discovering circulating cancer-associated immune signatures. This supports future development of immune-based diagnostics and disease monitoring approaches.

Abstract © the authors / Briefings in Bioinformatics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/bib/bbag320 · PubMed 42308424.

Why it matters for pharma & biotech

  • Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: AI in drug discovery / diagnostics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Briefings in Bioinformatics study find?

This supports future development of immune-based diagnostics and disease monitoring approaches.

What type of study is this?

It is a cohort / observational clinical study, published in Briefings in Bioinformatics in 2026. Compared with healthy donors, patients exhibited widespread immune dysregulation, including expansion of FOXP3+ regulatory T cells, depletion of CD16+CD11b+ monocytes and CD56^dim^ Natural killer (NK) cells, and elevated plasma IL-6 and IL-4 levels.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/bib/bbag320. PubMed ID: 42308424. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Berlin P, Mirzaei A, Steinbeck F et al.. Machine learning-guided multimodal profiling defines perturbed immune states at the time of cancer diagnosis.. Briefings in Bioinformatics (2026). DOI: 10.1093/bib/bbag320.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/machine-learning-guided-multimodal-profiling-defines-perturbed-immune-st-bag320/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides